verve lilly - Search News

News

Eli Lilly Buys Verve Therapeutics

The Motley Fool on MSN · 1h

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to acquire Verve. The deal centers on an exciting cardiovascular health medicine program,

The Wall Street Journal on MSN · 3d

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

Eli Lilly agreed to acquire Verve Therapeutics for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement, the pharmaceutical company will buy all of the gene-editing startup’s shares outstanding for $10.

Beyond Obesity: Eli Lilly’s Genetic Medicine Bet On Verve Therapeutics

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio.

Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug

Verve's top drug, Verve-102, is designed to target a gene called PCSK9, which is associated with heart health and cholesterol levels.

3don MSN

This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results